Literature DB >> 24969492

Current therapeutic approaches to cardio-protection in hypertension.

David Parra1, Augustus Hough.   

Abstract

Targeting a specific blood pressure based upon patient risk has been the approach to reducing cardiovascular risk in patients with hypertension. Drug selection was based upon compelling indications with titration and the addition of other agents as needed until the blood pressure target was achieved. However, new information has emerged describing improved methods for measuring blood pressure, a re-evaluation of blood pressure targets and additional therapeutic approaches that together may further reduce cardiovascular risk in patients with hypertension.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24969492     DOI: 10.1007/s11906-014-0457-5

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  75 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

2.  Effect of NR3C2 genetic polymorphisms on the blood pressure response to enalapril treatment.

Authors:  Jian-Quan Luo; Lu-Yan Wang; Fa-Zhong He; Ning-Ling Sun; Gen-Fu Tang; Jia-Gen Wen; Zhi-Ying Luo; Zhao-Qian Liu; Hong-Hao Zhou; Xiao-Ping Chen; Wei Zhang
Journal:  Pharmacogenomics       Date:  2013-09-23       Impact factor: 2.533

3.  Systolic blood pressure and cardiovascular outcomes during treatment of hypertension.

Authors:  Michael A Weber; George L Bakris; Allen Hester; Matthew R Weir; Tsushung A Hua; Dion Zappe; Bjorn Dahlof; Eric J Velazquez; Bertram Pitt; Kenneth Jamerson
Journal:  Am J Med       Date:  2013-03-28       Impact factor: 4.965

4.  The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension.

Authors:  Daniel G Hackam; Robert R Quinn; Pietro Ravani; Doreen M Rabi; Kaberi Dasgupta; Stella S Daskalopoulou; Nadia A Khan; Robert J Herman; Simon L Bacon; Lyne Cloutier; Martin Dawes; Simon W Rabkin; Richard E Gilbert; Marcel Ruzicka; Donald W McKay; Tavis S Campbell; Steven Grover; George Honos; Ernesto L Schiffrin; Peter Bolli; Thomas W Wilson; Ross D Feldman; Patrice Lindsay; Michael D Hill; Mark Gelfer; Kevin D Burns; Michel Vallée; G V Ramesh Prasad; Marcel Lebel; Donna McLean; J Malcolm O Arnold; Gordon W Moe; Jonathan G Howlett; Jean-Martin Boulanger; Pierre Larochelle; Lawrence A Leiter; Charlotte Jones; Richard I Ogilvie; Vincent Woo; Janusz Kaczorowski; Luc Trudeau; Robert J Petrella; Alain Milot; James A Stone; Denis Drouin; Kim L Lavoie; Maxime Lamarre-Cliche; Marshall Godwin; Guy Tremblay; Pavel Hamet; George Fodor; S George Carruthers; George B Pylypchuk; Ellen Burgess; Richard Lewanczuk; George K Dresser; S Brian Penner; Robert A Hegele; Philip A McFarlane; Mukul Sharma; Debra J Reid; Sheldon W Tobe; Luc Poirier; Raj S Padwal
Journal:  Can J Cardiol       Date:  2013-03-29       Impact factor: 5.223

5.  Effects of intensive blood-pressure control in type 2 diabetes mellitus.

Authors:  William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi
Journal:  N Engl J Med       Date:  2010-03-14       Impact factor: 91.245

6.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Authors: 
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

7.  The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators.

Authors:  E Ambrosioni; C Borghi; B Magnani
Journal:  N Engl J Med       Date:  1995-01-12       Impact factor: 91.245

8.  GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico.

Authors: 
Journal:  Lancet       Date:  1994-05-07       Impact factor: 79.321

9.  Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.

Authors:  David A Calhoun; Daniel Jones; Stephen Textor; David C Goff; Timothy P Murphy; Robert D Toto; Anthony White; William C Cushman; William White; Domenic Sica; Keith Ferdinand; Thomas D Giles; Bonita Falkner; Robert M Carey
Journal:  Hypertension       Date:  2008-04-07       Impact factor: 10.190

10.  2013 ambulatory blood pressure monitoring recommendations for the diagnosis of adult hypertension, assessment of cardiovascular and other hypertension-associated risk, and attainment of therapeutic goals.

Authors:  Ramón C Hermida; Michael H Smolensky; Diana E Ayala; Francesco Portaluppi
Journal:  Chronobiol Int       Date:  2013-04       Impact factor: 2.877

View more
  1 in total

1.  MEthods of ASsessing blood pressUre: identifying thReshold and target valuEs (MeasureBP): a review & study protocol.

Authors:  Kimberly C Blom; Sasha Farina; Yessica-Haydee Gomez; Norm R C Campbell; Brenda R Hemmelgarn; Lyne Cloutier; Donald W McKay; Martin Dawes; Sheldon W Tobe; Peter Bolli; Mark Gelfer; Donna McLean; Gillian Bartlett; Lawrence Joseph; Robin Featherstone; Ernesto L Schiffrin; Stella S Daskalopoulou
Journal:  Curr Hypertens Rep       Date:  2015-04       Impact factor: 5.369

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.